Market brief — September 25, 2026

Yesterday, the major equity benchmarks finished mixed-to-lower as the rates shock continued to dominate price action: the CAC 40 closed at 8,081.43 (-0.52%), the S&P 500 at 7,704.13 (-0.02%), the Nasdaq at 26,939.37 (+0.01%), the DAX at 25,266.53 (-0.57%), and the Euro Stoxx 50 at 6,272.50 (-0.43%). The market regime is still one of duration de-risking rather than growth optimism, with the latest moves reflecting a macro repricing driven by higher sovereign yields, not a clean risk-on tape.

The key transmission channel remains the bond market. Reuters reported early on September 25 that the U.S. 10-year yield had traded up around 5.19% after touching 5.2251%, while the 30-year reached 5.5016%, its highest since 2004, with the move linked to renewed inflation fears and stronger odds of further Fed tightening. That matters because higher long-end yields are compressing equity multiples, especially for long-duration and balance-sheet-sensitive names, while also keeping the dollar supported and limiting the upside in commodities and defensives. The current tape looks like a mix of systematic selling in rates-sensitive risk assets and selective discretionary buying in sectors with idiosyncratic catalysts; the divergence to watch is that equities are not collapsing even as yields probe multi-decade highs, which suggests positioning is already lighter than at the start of the month.

Today’s Cash Scanner reinforces that point. The leadership is concentrated in U.S. semiconductors and life-sciences tools, not broad cyclicals: Advanced Micro Devices (AMD) scored 40 with a +2.4% gap and a 20-day breakout, Intel Corp. (INTC) also scored 40 with a +3.9% gap and the same breakout signal, and Taiwan Semiconductor Manufacturing (TSM) scored 37 with volume and KST strength. In healthcare-adjacent momentum, 10x Genomics (TXG) scored 39 on an +11.2% gap with ADX 49, Agilent Technologies (A) scored 39 with a +4.5% gap, and Moderna (MRNA) scored 36 with an ADX 59 breakout. The scanner says leadership is narrow but constructive: the market is rewarding names with either powerful technical confirmation or clear fundamental catalysts, while ignoring broad beta. That is consistent with a regime in which investors are rotating toward secular growth pockets rather than adding index exposure.

Over the next 1–5 sessions, the dominant narrative is likely to remain “higher-for-longer, unless the bond market stabilizes.” Consensus already expects more pressure on long rates, but what may be underappreciated is how quickly equities can re-rate if the 10-year yield stops making new highs; a pause near the 5.10%–5.20% area would likely help the Nasdaq and the semiconductor complex more than the broader value trade. A contrarian scenario is that inflation anxiety keeps reaccelerating and the long bond continues to cheapen, which would likely widen the dispersion between momentum winners like AMD, INTC, and TSM and the rest of the market.

The most important catalysts are the next Treasury auction cycle, which can either confirm or relieve the duration stress; any fresh Fed communication that shifts the probability of another hike; U.S. inflation or spending data, which will directly affect front-end pricing; and Middle East / oil developments, because Brent near the $100 area keeps feeding the inflation impulse that is driving the bond selloff. Any upside surprise in oil or a weak auction would reinforce the current macro narrative, while softer inflation or a more stable long-bond auction could trigger a short-covering rally in duration-sensitive equities.

The main risks are a failed Treasury auction that pushes the 10-year decisively above the recent peak, a renewed oil spike that re-anchors inflation expectations, and a volatility pick-up that forces systematic de-risking across the crowded growth/quality factor complex. If the 10-year holds above 5.20% while the dollar firms and credit spreads widen, the current equity resilience should be treated as fragile rather than durable.

If the 10-year yield stays above 5.20% and the 30-year remains near 5.50%, the next upside move in equities is likely to be concentrated in technical momentum names rather than the index itself; that would keep AMD, INTC, TSM, and MRNA in relative leadership. If, instead, yields retreat and the VIX fails to extend, then the S&P 500’s near-flat close would look like a base rather than a top, and the market could finally broaden beyond the narrow scanner leaders. If Brent stabilizes below the recent stress zone, that would be the cleanest signal that the rates shock is easing and that the current de-risking phase is losing force.

Bonne journée aux p&l makers.